Thursday, April 2, 2026 – Friday, April 3 - A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis that it says shows the superiority of its own oral drug.
...
Thursday, April 2, 2026 – Friday, April 3 - (MedPage Today) -- As a primary care physician and obesity board-certified specialist, I believe that GLP-1s are one of the best medical interventions of all time, right up there with vaccines, antibiotics, blood thinners, and statins. They really...
Thursday, April 2, 2026 – Friday, April 3 - Potential import tariffs on drugs, Foundayo is here-o, and other biotech news from The Readout
Wednesday, April 1, 2026 – Thursday, April 2 - Eli Lilly and Co. anticipates shipping newly approved Foundayo (orforglipron) within the next week, as the drug becomes the second oral weight-loss glucagon-like peptide-1 (GLP-1) receptor agonist to enter the U.S. market following December’s approval of Novo Nordisk A/S’ Wegovy (semaglutide) pill.
Wednesday, April 1, 2026 – Thursday, April 2 - Wegovy (semaglutide) has passed the notoriously strict cost-effectiveness scrutiny of the U.K. health technology assessment body and will now be reimbursed for the prevention of further serious cardiovascular events in people who have had a heart attack or stroke, or are diagnosed with peripheral arterial disease.
Wednesday, April 1, 2026 – Thursday, April 2 - Physical activity is crucial when you’re taking this medication.
Wednesday, April 1, 2026 – Thursday, April 2 - (MedPage Today) -- The FDA has approved a second oral GLP-1 receptor agonist for weight loss in adults with obesity or overweight and weight-related comorbidities.
A once-daily tablet, orforglipron (Foundayo) is indicated in conjunction with a...
Wednesday, April 1, 2026 – Thursday, April 2 - Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.
Wednesday, April 1, 2026 – WEDNESDAY, April 1, 2026 -- For adults with type 2 diabetes (T2D) who were not achieving glycemic control while receiving a stable dose of dulaglutide, switching to tirzepatide is associated with improvement in patient-reported outcomes (PROs)...
Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly has previously said it plans to ...